Testosterone Therapy
Testosterone replacement for male hypogonadism (TRT)
For men with properly diagnosed hypogonadism, testosterone therapy produces modest but real benefits in sexual function, mood, bone density, and anaemia. It has no established benefit in men with normal levels, it impairs fertility, and it requires ongoing monitoring.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Moderate confidence
For men with properly diagnosed hypogonadism, testosterone therapy produces modest but real benefits in sexual function, mood, bone density, and anaemia. It has no established benefit in men with normal levels, it impairs fertility, and it requires ongoing monitoring.
Promising evidence that is still developing or context-dependent.
Biological Role
Testosterone's physiological roles in male sexual function, muscle, bone, and erythropoiesis are well established.
Human Evidence
Randomised trials in genuinely hypogonadal men — including the Testosterone Trials and the TRAVERSE cardiovascular safety trial — with modest effect sizes.
Benefit In Deficiency
Real but modest: improved sexual function, some benefit for mood, bone density, and anaemia. No cognitive benefit was found.
Benefit In Normal Levels
Not established. 'Optimising' testosterone in men who are not deficient has no demonstrated benefit and carries the same risks.
Safety Confidence
Cardiovascular non-inferiority was shown in TRAVERSE, but that trial also observed more atrial fibrillation, pulmonary embolism, and acute kidney injury. Fertility suppression is near-universal.
Research Activity
Active research on long-term cardiovascular and prostate outcomes, and on the boundary between deficiency and ageing.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
8/9
steps proven in humans
Evidence-rich
Proven at every applicable step — rare, and worth noticing.
Guideline / regulatory support
ProvenEndorsed for confirmed hypogonadism; explicitly not for ageing alone.
Clinical outcomes
LimitedSymptom benefit demonstrated; long-term hard outcomes still limited.
Large human RCTs
ProvenT-Trials and TRAVERSE.
Small human outcome trials
ProvenSymptom and body-composition outcomes.
Human safety data
ProvenSubstantial, including a dedicated cardiovascular safety trial.
Human biomarker / pharmacology
ProvenReliable restoration of levels; predictable haematocrit rise.
Animal
ProvenExtensive.
Cell / in vitro
ProvenAndrogen receptor biology established.
Mechanistic plausibility
ProvenHPG axis and androgen action well characterised.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
Genuine hypogonadism — confirmed low morning testosterone with symptoms — is a real condition, and replacing testosterone treats it. That is not in dispute.
What We Think
The benefits in properly diagnosed men are real but modest, and the most important clinical question is usually not 'should he have testosterone?' but 'why is it low?' Obesity, sleep apnoea, opioids, and alcohol are common, reversible causes.
What We Don't Know
The long-term cardiovascular and prostate consequences of years of therapy. TRAVERSE was reassuring on major cardiac events but raised questions about atrial fibrillation, clots, and kidney injury.
Active Research
Long-term safety, the boundary between age-related decline and true deficiency, and fertility-sparing alternatives for men who want children.
What Could Change Our Mind
Long-duration outcome data, and any trial demonstrating benefit in men with normal baseline testosterone — which does not currently exist.
The biggest myth
“Testosterone therapy improves cognition”
The Testosterone Trials specifically examined cognition in older men with low testosterone and found no benefit.
Ask BioSignal
Still have a question about testosterone therapy?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take testosterone therapy
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
Testosterone has become the centrepiece of a large men's-health market that promises energy, muscle, and vitality. The honest picture: it is a genuinely effective treatment for a genuine, diagnosable deficiency — and there is no evidence it does anything good for men who do not have that deficiency, while it reliably does one thing they may not want, which is to suppress their fertility.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
FDA-approved for classical hypogonadism due to disease of the testes, pituitary, or hypothalamus — not for age-related decline
Availability
Prescription only (a controlled substance in many jurisdictions)
Sport (WADA)
PROHIBITED at all times in sport (anabolic agent) — confirm against the current list
Known safety profile
Testosterone therapy has a manageable but real risk profile that requires ongoing monitoring. The most certain harm — fertility suppression — is also the least discussed.
Common issues
- Suppression of sperm production and infertility
- Raised haematocrit (thickened blood) requiring monitoring
- Acne and oily skin
- Testicular shrinkage
- Worsening of obstructive sleep apnoea
- Gel formulations can transfer to partners and children by skin contact
Use caution if
- Men who want to father children (therapy suppresses fertility)
- Men with untreated obstructive sleep apnoea
- Men with a history of blood clots or atrial fibrillation
- Men with prostate cancer or an unevaluated raised PSA
- Men with severe heart failure
- Men with elevated haematocrit
Long-term unknowns
Cardiovascular and prostate outcomes over decades of therapy are not fully characterised. TRAVERSE ran for a limited period and its atrial fibrillation and thromboembolism signals are not fully resolved.
Limits of this evidence
The trial evidence is in men with genuine deficiency, and cannot be extrapolated to men with normal levels — which is precisely the population the commercial 'optimisation' market serves. Benefits in properly diagnosed men are modest, and are often presented as far larger than the trials support.
Full regulatory and sport detail
- Regulatory approval
- Approved for men with hypogonadism due to disorders of the testes, pituitary, or hypothalamus. Regulators have explicitly stated that benefit and safety have NOT been established for low testosterone due to ageing alone.
- Approved indication
- Classical (organic) male hypogonadism.
- Investigational
- Fertility-sparing approaches and long-term outcome studies remain under investigation.
- Research chemical
- N/A — a licensed medicine; also widely sold illicitly, where purity and dosing are unverified.
- Sport (WADA)
- PROHIBITED at all times in sport as an anabolic agent — confirm against the current list.
- Publication note
- Re-confirm regulatory and anti-doping status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 9 popular claims about testosterone therapy.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 2
- Not established
- 7
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Testosterone therapy improves symptoms in men with genuine hypogonadism
- Testosterone therapy suppresses sperm production and can cause infertility
Not established
- Testosterone therapy improves cognition
- Testosterone therapy causes heart attacks
- Testosterone therapy is completely safe
- Low testosterone in middle-aged men usually means they need testosterone
- Testosterone therapy is an anti-ageing treatment
- Testosterone therapy causes prostate cancer
- A single low testosterone reading is enough to diagnose deficiency
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Testosterone therapy improves symptoms in men with genuine hypogonadismSupportedModerate confidence
In men with confirmed low testosterone and symptoms, therapy improves sexual function and produces smaller benefits for mood, bone density, and anaemia. Effect sizes are modest, not transformative.
Testosterone therapy suppresses sperm production and can cause infertilitySupportedHigh confidence
Exogenous testosterone suppresses the pituitary signals that drive spermatogenesis, markedly reducing sperm production — often to zero. This is the most under-disclosed fact about the therapy, and it can take many months to reverse.
Testosterone therapy causes heart attacksNot establishedModerate confidence
The TRAVERSE trial, designed to answer this in men with hypogonadism and cardiovascular risk, found testosterone non-inferior to placebo for major adverse cardiac events. This was genuinely reassuring — but it is not the same as showing the therapy is free of cardiovascular consequence.
Testosterone therapy is completely safeNot establishedModerate confidence
TRAVERSE observed more atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. Therapy also raises haematocrit, requiring monitoring. It is a manageable risk profile, not an absent one.
Low testosterone in middle-aged men usually means they need testosteroneNot establishedModerate confidence
Much low testosterone is functional — driven by obesity, obstructive sleep apnoea, opioids, alcohol, or illness — and improves when the cause is treated. Prescribing testosterone treats the number while the cause continues.
Testosterone therapy is an anti-ageing treatmentNot establishedModerate confidence
There is no established benefit in men with normal testosterone levels. Age-related decline in testosterone is not the same condition as hypogonadism, and treating it as such is not supported.
Testosterone therapy causes prostate cancerNot establishedLimited evidence
Current evidence does not show that testosterone therapy causes prostate cancer, though monitoring is still recommended and long-term data remain limited. The historical fear appears to have been overstated — but 'not shown to cause' is not 'shown to be safe'.
A single low testosterone reading is enough to diagnose deficiencyNot establishedHigh confidence
It is not. Testosterone follows a diurnal rhythm and varies day to day. Diagnosis requires at least two low morning fasting measurements together with symptoms — and interpretation of total testosterone requires knowing SHBG.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Men with confirmed hypogonadism
- Intervention
- Testosterone gel (transdermal)
- Dose
- Clinician-titrated to mid-normal range
- Duration
- Long-term, with monitoring
- Outcome
- Symptoms; testosterone level in physiological range
- Notes
- Titration targets the normal range — not supraphysiological levels. Risk of transfer to others by skin contact
Men with confirmed hypogonadism
- Intervention
- Testosterone injection (intramuscular or subcutaneous)
- Dose
- Clinician-directed; regimens vary by ester
- Duration
- Long-term, with monitoring
- Outcome
- Symptoms; testosterone level in physiological range
- Notes
- Longer-acting esters give steadier levels; shorter-acting esters produce peaks and troughs
Men who wish to preserve fertility
- Intervention
- Alternatives to testosterone (clinician-directed)
- Dose
- Not testosterone
- Duration
- Clinician-directed
- Outcome
- Symptoms while preserving spermatogenesis
- Notes
- Testosterone suppresses fertility. Men who want children need a different conversation — this is the single most important consultation point
Men with normal testosterone
- Intervention
- Testosterone for 'optimisation'
- Dose
- Not established
- Duration
- Not established
- Outcome
- No demonstrated benefit
- Notes
- No dose is established because no benefit is established in this group
Where scientists agree — and don’t
Agreed
- Testosterone therapy is indicated for men with confirmed hypogonadism — low morning testosterone plus symptoms.
- Diagnosis requires repeat morning fasting measurements, not a single result.
- Therapy suppresses spermatogenesis and impairs fertility.
- Functional causes of low testosterone (obesity, sleep apnoea, opioids) should be identified and addressed.
- Haematocrit requires monitoring.
Debated
- Where the boundary lies between age-related decline and true deficiency.
- The clinical significance of the atrial fibrillation and thromboembolism signals in TRAVERSE.
- How aggressively to treat borderline levels in symptomatic men.
Unknown
- Long-term cardiovascular and prostate outcomes over decades of therapy.
- Whether any subgroup with normal testosterone benefits.
- The optimal target level within the normal range.
What remains unknown
- What are the long-term cardiovascular and prostate consequences of therapy over decades?
- Do the atrial fibrillation and pulmonary embolism signals from TRAVERSE reflect causal harm?
- Where exactly is the line between age-related decline and treatable hypogonadism?
- Can symptomatic men be treated effectively without suppressing fertility?
Questions people actually ask
What is testosterone therapy?
It is replacement of testosterone — by gel, injection, or other routes — in men whose bodies do not produce enough. It is a treatment for a diagnosed deficiency called hypogonadism, not a supplement and not a performance enhancer.
How is low testosterone properly diagnosed?
With at least two low morning, fasting testosterone measurements together with symptoms — never a single reading, because levels vary through the day and from day to day. SHBG matters too: obesity lowers SHBG, which can make total testosterone look low when the active free fraction is normal. LH and FSH are then measured to work out whether the problem is in the testes or in the pituitary.
Will testosterone therapy affect my fertility?
Almost certainly, and this is the most important thing to understand before starting. Exogenous testosterone switches off the pituitary signals that drive sperm production, often reducing sperm counts to zero. Recovery can take many months and is not guaranteed. If you may want children, say so before you start — there are other approaches.
My testosterone is low. Do I need therapy?
Not necessarily — and the more useful question is why it is low. Obesity, obstructive sleep apnoea, opioids, heavy alcohol use, and acute illness all suppress testosterone, and treating those often restores it. Starting testosterone in that situation treats the number while leaving the cause running.
Does testosterone therapy cause heart attacks?
The TRAVERSE trial was designed to answer exactly this in men with hypogonadism and cardiovascular risk, and it found testosterone non-inferior to placebo for major cardiac events. That is genuinely reassuring. It is not, however, a clean bill of health: the same trial saw more atrial fibrillation, pulmonary embolism, and acute kidney injury.
Practical takeaways
- Testosterone therapy genuinely works — for men who genuinely have hypogonadism.
- Diagnosis needs two low morning readings plus symptoms, interpreted alongside SHBG.
- Ask why testosterone is low first: obesity, sleep apnoea, opioids, and alcohol are common and reversible.
- It suppresses sperm production — decisive if you want children, and often not mentioned.
- There is no established benefit for men with normal levels. 'Optimisation' is a marketing concept, not a clinical one.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
Testosterone's physiological roles in male sexual function, muscle, bone, and erythropoiesis are well established.
How we found out
Established Endocrinology
Testosterone's role and the consequences of its deficiency were characterised, and replacement became standard treatment for genuine hypogonadism.
The Testosterone Trials
Randomised trials in older men with low testosterone found modest benefits for sexual function, mood, bone density, and anaemia — and specifically no cognitive benefit.
The Commercial Expansion
Direct-to-consumer clinics extended testosterone prescribing far beyond diagnosed hypogonadism, reframing age-related decline as a treatable deficiency.
TRAVERSE and the Safety Question
A large cardiovascular safety trial found testosterone non-inferior for major cardiac events in hypogonadal men, while observing increases in atrial fibrillation, pulmonary embolism, and acute kidney injury.
References
Verified sources. BioSignal does not print a citation it has not checked.
References for this record are being verified and will be published with the next review. BioSignal does not print citations it has not checked.
Version history
Version 1.0
Initial record for the Hormonal Health Ecosystem, authored to the Creatine benchmark. Calibration: Established maturity for its licensed indication, moderate confidence. Fertility suppression is elevated into the claims and questions surfaces because it is the most consequential under-disclosed fact. Review cadence: Annually.
Continue exploring
Three places this record leads next.